The Conversation (0)
PDS Biotechnology Corporation presented its preclinical data on its PDS0101 at the World Vaccine Congress in Washington DC based on its proprietary Versamune ™ vaccine platform. The company also announced that the FDA has approved its IND application for the immunotherapy to be evaluated in human patients.
PDS Biotechnology Corporation presented its preclinical data on its PDS0101 at the World Vaccine Congress in Washington DC based on its proprietary Versamune ™ vaccine platform. The company also announced that the FDA has approved its IND application for the immunotherapy to be evaluated in human patients.
As quoted in the press release:
PDS0101 is a first-in-class immunotherapy being developed to treat cancers and diseases caused by infection with the human papillomavirus such as cervical cancer, head and neck cancer and cervical intraepithelial neoplasia. Dr. Frank Bedu-Addo, President and CEO presented the highly promising preclinical efficacy and safety data demonstrating eradication of the tumors without any of the safety drawbacks typical of the current immunotherapy technologies. PDS0101 is designed to prime the immune system to recruit cells of the body’s own immune system to specifically recognize, target and kill the cancer cells. PDS0101 is also designed to reduce the population of certain immune suppressive cells which prevent our immune systems from detecting and attacking the cancer cells. “Should the preclinical results be replicated in the clinical setting, this will be a giant leap forward in the development of safe and effective cancer therapies,” said Frank Bedu-Addo.
Click here to read the full PDS Biotechnology Corporation press release.
